首页> 外文期刊>Bone marrow transplantation >Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation.
【24h】

Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation.

机译:低剂量TBI和T细胞减少的同种异体外周干细胞移植的非清髓性调理后持续植入失败。

获取原文
获取原文并翻译 | 示例
           

摘要

We investigated whether a T cell-reduced allogeneic stem cell transplant (SCT) with minimal conditioning and subsequent donor lymphocyte infusions (DLI) could reduce the incidence and severity of GVHD while retaining stable engraftment. Five patients with hematological malignancies (three MM, one CLL, one Chediak-Higashi syndrome) were conditioned with TBI (200 cGy). One patient additionally received fludarabine (120 mg/m(2)). CsA and mofetyl-mycophenolate (MMF) were administered to prevent GVHD. All patients were grafted with >3 x 10(6)/kg highly purified CD34(+) cells together with 2 x 10(6)/kg CD3(+) cells (three patients) or 1 x 10(5)/kg CD3(+) cells (two patients). Quick hematopoietic recovery and initial mixed donor chimerism was observed. Treatment-related toxicity was minimal in all but one patient who died of treatment-refractory GVHD on day 112. The four other patients only achieved partial donor T cell chimerism. BM and PBMC donor chimerism was lost between day 40 and 209 despite DLI. Three patients are alive with disease and one is in CR. We conclude that T cell-reduced SCT using 200 cGy as the conditioning regimen does not result in stable hematopoietic engraftment. Predominant donor T cell chimerism is not a prerequisite for initial allogeneic hematopoietic proliferation. However for sustained long-term engraftment it is of major importance.
机译:我们调查了是否以最少的调节和随后的供体淋巴细胞输注(DLI)进行了T细胞减少的同种异体干细胞移植(SCT)可以降低GVHD的发生率和严重程度,同时又能保持稳定的植入。 5例血液系统恶性肿瘤患者(3例MM,1例CLL,1例Chediak-Higashi综合征)接受TBI(200 cGy)治疗。 1名患者另外接受了氟达拉滨(120 mg / m(2))。给予CsA和Mofetyl-霉酚酸酯(MMF)预防GVHD。所有患者均移植了> 3 x 10(6)/ kg高纯度CD34(+)细胞以及2 x 10(6)/ kg CD3(+)细胞(三名患者)或1 x 10(5)/ kg CD3 (+)个细胞(两名患者)。观察到快速的造血恢复和最初的混合供体嵌合。除在第112天死于治疗难治性GVHD的一名患者外,与治疗相关的毒性微乎其微。其他四名患者仅实现部分供体T细胞嵌合。尽管有DLI,但BM和PBMC供体嵌合在第40天到209天之间消失了。 3名患者还活着,其中1名患有CR。我们得出的结论是,使用200 cGy作为调理方案的T细胞减少的SCT不会导致稳定的造血移植。主要的供体T细胞嵌合不是初始异体造血增殖的先决条件。然而,对于持续的长期移植来说,这是非常重要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号